MX2012007009A - Método para diagnosticar un tumor maligno. - Google Patents
Método para diagnosticar un tumor maligno.Info
- Publication number
- MX2012007009A MX2012007009A MX2012007009A MX2012007009A MX2012007009A MX 2012007009 A MX2012007009 A MX 2012007009A MX 2012007009 A MX2012007009 A MX 2012007009A MX 2012007009 A MX2012007009 A MX 2012007009A MX 2012007009 A MX2012007009 A MX 2012007009A
- Authority
- MX
- Mexico
- Prior art keywords
- recurrence
- malignant tumor
- tumor
- malignous
- diagnosing
- Prior art date
Links
Classifications
-
- G01N33/575—
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- G01N33/57505—
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/54—Determining the risk of relapse
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Endocrinology (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Hospice & Palliative Care (AREA)
- Measuring And Recording Apparatus For Diagnosis (AREA)
- Medical Treatment And Welfare Office Work (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
Abstract
Para proporcionar un método y un kit de diagnóstico para determinar la presencia de un tumor maligno o la severidad del mismo, un método para seleccionar un método terapéutico contra el mismo o para evaluar el efecto de método terapéutico, o un método para estimar el riesgo de recurrencia del tumor maligno o para determinar la presencia o ausencia de la recurrencia; el método para determinar la presencia de un tumor maligno o la severidad del mismo, el método para seleccionar un método terapéutico contra el mismo o para evaluar el efecto del método terapéutico, o el método para calcular el riesgo de recurrencia del tumor maligno o la presencia o ausencia de la recurrencia, se caracterizan porque incluyen 1) un paso para medir la concentración y/o cantidad de LR11 soluble en una muestra proveniente de un sujeto, y 2) un paso para comparar el valor obtenido arriba con un valor de medición de LR11 soluble obtenido de un grupo de sujetos sanos.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2009285492 | 2009-12-16 | ||
| JP2010120390 | 2010-05-26 | ||
| PCT/JP2010/072521 WO2011074594A1 (ja) | 2009-12-16 | 2010-12-15 | 悪性腫瘍の診断方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2012007009A true MX2012007009A (es) | 2012-07-03 |
Family
ID=44167345
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012007009A MX2012007009A (es) | 2009-12-16 | 2010-12-15 | Método para diagnosticar un tumor maligno. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9097714B2 (es) |
| EP (1) | EP2515114B1 (es) |
| JP (1) | JP5783909B2 (es) |
| KR (1) | KR101832199B1 (es) |
| CN (1) | CN102656456B (es) |
| AU (1) | AU2010331291B2 (es) |
| BR (1) | BR112012014954B1 (es) |
| CA (1) | CA2783308C (es) |
| MX (1) | MX2012007009A (es) |
| RU (1) | RU2595854C2 (es) |
| WO (1) | WO2011074594A1 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9969802B2 (en) | 2010-07-15 | 2018-05-15 | Sekisui Medical Co., Ltd. | Method for detecting malignant tumor cells |
| WO2012008595A1 (ja) * | 2010-07-15 | 2012-01-19 | 積水メディカル株式会社 | 抗ｌｒ１１抗体の製造法及び免疫学的測定用標準品 |
| US9541550B2 (en) | 2011-05-09 | 2017-01-10 | Sekisui Medical Co., Ltd. | Method for immunologically measuring soluble LR11 |
| JP6041297B2 (ja) * | 2012-08-24 | 2016-12-07 | 国立大学法人山口大学 | 犬リンパ腫の診断方法及び診断キット |
| JP6116938B2 (ja) * | 2013-02-28 | 2017-04-19 | 学校法人順天堂 | 新規な肺高血圧症のマーカー |
| JP6166062B2 (ja) * | 2013-02-28 | 2017-07-19 | 積水メディカル株式会社 | 肝臓疾患の評価方法及び診断キット |
| RU2662709C1 (ru) * | 2016-06-27 | 2018-07-26 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Ивановская государственная медицинская академия" Министерства здравоохранения Российской Федерации | Способ диагностики дисплазии и рака шейки матки у женщин репродуктивного возраста |
| RU2663309C1 (ru) * | 2016-06-27 | 2018-08-03 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Ивановская государственная медицинская академия" Министерства здравоохранения Российской Федерации | Способ диагностики крауроза вульвы у женщин в менопаузе |
| CN113196057B (zh) * | 2018-11-09 | 2024-09-06 | 积水医疗株式会社 | 病毒性肝癌的检测方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH09163988A (ja) | 1995-10-09 | 1997-06-24 | Kowa Co | 新規なｌｄｌ受容体類似蛋白質及び遺伝子 |
| DE10136273A1 (de) * | 2001-07-25 | 2003-02-13 | Sabine Debuschewitz | Molekulare Marker beim hepatozellulären Karzinom |
| AU2002359310A1 (en) * | 2001-10-26 | 2003-05-06 | Immunex Corporation | Treating diseases mediated by metalloprotease-shed proteins |
| AU2003275946A1 (en) * | 2002-11-01 | 2004-05-25 | Aros Applied Biotechnology Aps | Gene expression in biological conditions |
| WO2005015236A2 (en) * | 2003-07-18 | 2005-02-17 | Roche Diagnostics Gmbh | A method for predicting the progression of adenocarcinoma |
| EP2159577B1 (en) | 2007-06-18 | 2012-08-08 | Sekisui Medical Co., Ltd. | Novel marker for arteriosclerotic disease |
| WO2009116268A1 (ja) | 2008-03-21 | 2009-09-24 | 積水メディカル株式会社 | 可溶性ｌｒ１１の定量方法 |
| WO2011027308A1 (en) * | 2009-09-03 | 2011-03-10 | Koninklijke Philips Electronics N.V. | Novel tumor markers |
-
2010
- 2010-12-15 US US13/512,903 patent/US9097714B2/en active Active
- 2010-12-15 WO PCT/JP2010/072521 patent/WO2011074594A1/ja not_active Ceased
- 2010-12-15 EP EP10837620.3A patent/EP2515114B1/en not_active Not-in-force
- 2010-12-15 MX MX2012007009A patent/MX2012007009A/es active IP Right Grant
- 2010-12-15 RU RU2012129913/15A patent/RU2595854C2/ru active
- 2010-12-15 AU AU2010331291A patent/AU2010331291B2/en not_active Ceased
- 2010-12-15 CA CA2783308A patent/CA2783308C/en active Active
- 2010-12-15 KR KR1020127010487A patent/KR101832199B1/ko not_active Expired - Fee Related
- 2010-12-15 JP JP2011546140A patent/JP5783909B2/ja active Active
- 2010-12-15 BR BR112012014954-7A patent/BR112012014954B1/pt not_active IP Right Cessation
- 2010-12-15 CN CN201080056852.2A patent/CN102656456B/zh not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| AU2010331291B2 (en) | 2016-04-14 |
| RU2012129913A (ru) | 2014-01-27 |
| CA2783308C (en) | 2018-10-16 |
| CN102656456A (zh) | 2012-09-05 |
| US20130029363A1 (en) | 2013-01-31 |
| KR101832199B1 (ko) | 2018-04-13 |
| EP2515114A1 (en) | 2012-10-24 |
| EP2515114A4 (en) | 2012-12-05 |
| JPWO2011074594A1 (ja) | 2013-04-25 |
| WO2011074594A1 (ja) | 2011-06-23 |
| AU2010331291A1 (en) | 2012-06-21 |
| JP5783909B2 (ja) | 2015-09-24 |
| CA2783308A1 (en) | 2011-06-23 |
| BR112012014954A2 (pt) | 2016-12-13 |
| KR20120123248A (ko) | 2012-11-08 |
| BR112012014954B1 (pt) | 2020-11-24 |
| EP2515114B1 (en) | 2017-11-15 |
| US9097714B2 (en) | 2015-08-04 |
| CN102656456B (zh) | 2015-04-08 |
| RU2595854C2 (ru) | 2016-08-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2012007009A (es) | Método para diagnosticar un tumor maligno. | |
| PH12018550037A1 (en) | Quencher containing water-soluble polymer-conjugated nanomaterial and use thereof | |
| MX360236B (es) | Uso de marcadores en el diagnostico y tratamiento de cancer de prostata. | |
| GB2463401B (en) | Characterizing prostate disorders by analysis of microvesicles | |
| AR095363A1 (es) | Biomarcadores y métodos para el tratamiento de condiciones relacionadas con pd-1 y pd-l1 | |
| NZ607282A (en) | Method for using gene expression to determine prognosis of prostate cancer | |
| MX2015012303A (es) | Un metodo no invasivo para medir el estres oxidativoy daño oxidativo de los biomarcadores cutaneos. | |
| CR20130070A (es) | Ensayos biomarcadores para detectar o medir inhibición de actividad quinasa tor | |
| MY188938A (en) | Therapeutic, diagnostic and prognostic methods for cancer of the bladder | |
| MX361058B (es) | Método para detectar células tumorales circulantes 5t4-positivas y métodos de diagnóstico de cáncer 5t4-positivo en un sujeto mamífero. | |
| WO2009137807A3 (en) | Compositions and methods related to mirna modulation of neovascularization or angiogenesis | |
| BR112013000760A2 (pt) | método e aparelho para medir a espessura do tecido adiposo | |
| MX361731B (es) | Método para diagnosticar cáncer y kit de diagnóstico usando medición de actividad de células nk. | |
| WO2015031808A3 (en) | Diagnostic methods and compositions for treatment of glioblastoma | |
| JP2014144959A5 (es) | ||
| CA2863393A1 (en) | A multi-biomarker-based outcome risk stratification model for pediatric septic shock | |
| EP3159695A3 (en) | Methods for diagnosing pancreatic cancer | |
| IN2012DN03817A (es) | ||
| WO2010136163A8 (en) | Secernin-1 as a marker for cancer | |
| MX2017005126A (es) | Metodos y composiciones para el diagnostico y pronostico de lesion renal e insuficiencia renal. | |
| MX2017003370A (es) | Composiciones, metodos y kits para el diagnostico de una neoplasia neuroendocrina gastroenteropancreatica. | |
| NZ716643A (en) | Methods for predicting the risk of having a cardiovascular event and for monitoring the treatment of a cardiovascular event | |
| GB201014837D0 (en) | Biomarker signatures and uses thereof | |
| WO2011052906A3 (en) | Use of eif3m for the diagnosis and treatment of cancer | |
| BR112016013976A2 (pt) | método para determinar se um indivíduo é afetado por um câncer, método para discriminar entre câncer colorretal e pancreático dentre indivíduos que resultam ser positivos para o método, método para determinar o estágio de um câncer colorretal em um indivíduo afetado e uso de um kit de rt-pcr quantitativo para performar o método |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |